Keryx Biopharmaceuticals (KERX)
Keryx Biopharmaceuticals Dividend Yield: 0.00%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
KERX Dividend Yield Rankings
| Overall | 57th percentile | 1998 of 4671 |
| Sector | 85th percentile | 77 of 525 in Healthcare |
| Industry | 59th percentile | 11 of 27 in Drug Manufacturers - Major |
KERX Dividend Yield Range, Past 5 Years
| Minimum | 0.00% | Jun 2007 |
| Maximum | 0.00% | Jun 2007 |
| Average | 0.00% |
About Dividend Yield
The dividend yield is the sum company's annual dividends per share, divided by the current price per share. It is often expressed as a percentage. It the reciprocal of the price/dividend ratio. By investing in a company with a high dividend yield, investors can secure a relatively stable cash flow. However, it is important to note that sometimes dividend yields are high when a company is facing financial trouble, and the company may cut the dividend in the near future.
For example, if a stock trades at $36 and pays $1.80 in dividends over the course of one year ($.45 per quarter), the company's dividend yield is 5%.
Learn More
You may also be interested in these KERX related companies
KERX News
@newkidontheblock hey man i know, keeping my $kerx, thot of dumpg $athx but 'heavy vol' on them, wanted to buy even more $arna, we'll see
about 3 hours ago by milroyt
about 3 hours ago by milroyt
$AMRN $kerx $arna $gale going golfing get my mind off this shiz for a bit. See u bounce back when I'm back
about 7 hours ago by newkidontheblock
about 7 hours ago by newkidontheblock
$ARNA $kerx $amrn $gale expect green today no reason to be red
about 8 hours ago by newkidontheblock
about 8 hours ago by newkidontheblock
@newkidontheblock $KERX when will this stock rise to the occasion?
about 8 hours ago by GucciMoccasins
about 8 hours ago by GucciMoccasins
$kerx if not I'm adding to this position trying get to 20k shares by end of June still in effect
about 8 hours ago by newkidontheblock
about 8 hours ago by newkidontheblock
$KERX and i was thinking 2, two weeks ago! I was wrong. counting on u being right
about 19 hours ago by Bleedblue
about 19 hours ago by Bleedblue
$AMRN $kerx $arna $gale bullish on all with FDA Asco such events on the way
about 19 hours ago by newkidontheblock
about 19 hours ago by newkidontheblock
Ceo has over 400k shares conditional upon positive zerenex and fda approval. Thats a big carrot! $kerx is best when volume dry and lonely...
about 19 hours ago by HighRiskBuyer
about 19 hours ago by HighRiskBuyer
RT @gregthor $KERX must have been a helluva presentation this past weekend. Get far wealthier trading other stocks thn $KERX (POS).
about 22 hours ago by JasonMilano8
about 22 hours ago by JasonMilano8
@adamfeuerstein @Gekkowire what do these free shares mean? $kerx
about 23 hours ago by GucciMoccasins
about 23 hours ago by GucciMoccasins
$KERX must have been a helluva presentation this past weekend. Get far wealthier trading other stocks thn $KERX (POS).
about a day ago by gregthor
about a day ago by gregthor
$KERX Stock better run soon ugh money tied up is less money to be had
about a day ago by newkidontheblock
about a day ago by newkidontheblock
M&A Activity and Growing Rate of FDA Approvals Contributing Factors to Biotech Industry's Recent Boom
May 21, 8:20AM Marketwire
May 21, 8:20AM Marketwire
BMC Software, The Ultimate Software Group Included in Stocks Up on High Volume Monday
May 14, 12:33PM Fox Business
May 14, 12:33PM Fox Business
Morning Movers 05/14: (GOLF) (VTUS) (KERX) Higher; (IOC) (ACOM) (ANIK) Lower
May 14, 10:07AM Street Insider
May 14, 10:07AM Street Insider
Unusual 11 Mid-Day Movers 05/10: (ADY) (INSP) (RPRX) Higher; (SGI) (WFR) (ARX) Lower
May 10, 2:24PM Street Insider
May 10, 2:24PM Street Insider
UPDATE: Ladenburg Thalmann Upgrades Keryx Biopharmaceuticals; Establishes PT
May 10, 10:54AM Benzinga
May 10, 10:54AM Benzinga
Keryx Biopharmaceuticals to Present at The 11th Annual JMP Securities Research Conference
May 10, 8:30AM PR Newswire
May 10, 8:30AM PR Newswire
Aeterna (AEZS), Keryx (KERX) Terminate Perifosine License Agreement in North America
May 07, 7:40AM Street Insider
May 07, 7:40AM Street Insider
Pharmaceutical Companies Look to Biotech Industry to Combat Losses From Expiring Patents
Apr 23, 8:20AM Marketwire
Apr 23, 8:20AM Marketwire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| KERX | 1.65 | -0.05 | -2.94% | 120.73M |
| KEQU | 8.25 | -0.02 | -0.24% | 21.28M |
| KEP | 9.40 | -0.12 | -1.26% | 12.22B |
| KEM | 5.58 | -0.16 | -2.79% | 256.35M |
| KELYB | 12.06 | -0.32 | -2.58% | 467.96M |
| KELYA | 11.99 | -0.39 | -3.15% | 456.95M |
| KEG | 9.94 | -0.82 | -7.62% | 1.629B |
| KDN | 22.62 | -0.34 | -1.48% | 733.57M |
| JNPR | 17.26 | -0.14 | -0.83% | 9.164B |
| JNK | 38.53 | -0.18 | -0.46% |
